Amgen is a biopharmaceutical company based in Thousand Oaks, California. It is one of the largest companies in the world and is listed on the Dow Jones Industrial Average. The company develops, manufactures, and markets medically necessary biopharmaceuticals and has a strong presence in the healthcare industry. Amgen is known for its innovative products and therapies that improve the lives of patients suffering from various diseases.
AMGEN Stock Price
Introduction to Amgen
Amgen was founded in 1980 and since then, it has been at the forefront of medical innovation. The company has a diversified product portfolio that includes treatments for a range of diseases such as cancer, anemia, osteoporosis, and inflammation. It also has a strong focus on developing personalized medicines and therapies that are tailored to the individual needs of patients.
Amgen has a long track record of success and is a respected name in the healthcare industry. It is one of the few companies that is listed on the Dow Jones Industrial Average. This means that it is considered to be one of the most successful companies in the world.
The company has a strong presence in the United States and Europe and is expanding its operations in Asia Pacific. It has a diversified product portfolio and a large network of research and development centers. This means that the company is well-positioned to take advantage of the growing demand for biopharmaceuticals in the global market.
Amgen’s Performance & Stock Price
Amgen’s stock price has been on a steady rise and down on latest months over the past few years. In the last 12 months, the stock price has down by more than 1.48%.
Amgen financials summary report show a market cap of 126.87B, sales 26.32B, Dividend 3.55% and EPS (ttm) of 12.11 and also SMA20 -5.87%, SMA50 -9.80% and SMA200 -6.53%.
What Makes Amgen an Attractive Investment?
One of the reasons why Amgen is an attractive investment is its strong performance in the market. The company has consistently delivered strong returns to its shareholders over the past few years. As a result, investors have been able to benefit from the company’s growth and have seen a steady increase in their investments.
In addition, the company has a strong presence in the global market. It has a diversified product portfolio and a large network of research and development centers. This ensures that the company is well-positioned to take advantage of the growing demand for biopharmaceuticals in the global market.
Finally, the company is a Dow listed company, which means that it is considered to be one of the most successful companies in the world. This gives investors the assurance that they are investing in a company that is well-positioned for long-term success.
Amgen’s Financials
Amgen has a balance sheet, with a debt-to-equity ratio of 10.64.
| Index | DJIA, NDX, S&P 500 | P/E | 19.82 | EPS (ttm) | 12.11 | Insider Own | 0.21% | Shs Outstand | 535.00M | Perf Week | -1.55% |
| Market Cap | 126.87B | Forward P/E | 12.75 | EPS next Y | 18.83 | Insider Trans | -0.70% | Shs Float | 532.74M | Perf Month | -10.63% |
| Income | 6.55B | PEG | 3.91 | EPS next Q | 3.99 | Inst Own | 79.10% | Short Float / Ratio | 1.48% / 3.05 | Perf Quarter | -16.68% |
| Sales | 26.32B | P/S | 4.82 | EPS this Y | 17.80% | Inst Trans | -1.49% | Short Interest | 7.90M | Perf Half Y | -5.70% |
| Book/sh | 6.84 | P/B | 35.10 | EPS next Y | 5.89% | ROA | 10.60% | Target Price | 261.03 | Perf Year | 5.51% |
| Cash/sh | 17.61 | P/C | 13.63 | EPS next 5Y | 5.07% | ROE | 246.10% | 52W Range | 214.39 – 296.67 | Perf YTD | -10.03% |
| Dividend | 8.52 | P/FCF | 27.65 | EPS past 5Y | 2.00% | ROI | 20.60% | 52W High | -20.35% | Beta | 0.64 |
| Dividend % | 3.55% | Quick Ratio | 1.10 | Sales past 5Y | 2.90% | Gross Margin | 75.70% | 52W Low | 10.21% | ATR | 4.75 |
| Employees | 25200 | Current Ratio | 1.40 | Sales Q/Q | -0.10% | Oper. Margin | 36.60% | RSI (14) | 23.24 | Volatility | 1.37% 1.88% |
| Optionable | Yes | Debt/Eq | 10.64 | EPS Q/Q | -10.80% | Profit Margin | 24.90% | Rel Volume | 0.77 | Prev Close | 240.07 |
| Shortable | Yes | LT Debt/Eq | 10.20 | Earnings | Jan 31 AMC | Payout | 63.70% | Avg Volume | 2.59M | Price | 236.29 |
| Recom | 2.70 | SMA20 | -5.27% | SMA50 | -9.80% | SMA200 | -6.53% | Volume | 405,126 | Change | -1.57% |
The Advantages of Investing in Amgen
Investing in Amgen has several advantages. Firstly, the company is a Dow listed company, which means that it is considered to be one of the most successful companies in the world. This gives investors the assurance that they are investing in a company that is well-positioned for long-term success.
In addition, the company has a strong balance sheet and a debt-to-equity ratio of 0.47. This indicates that the company is in a strong financial position and is well-positioned to take advantage of growth opportunities in the future.
Furthermore, the company has a strong track record of delivering value to its shareholders. In the last 12 months, the company’s stock price has increased by more than 27%. This is a reflection of the company’s strong performance and its ability to capitalize on opportunities in the market.
Finally, the company has a diversified product portfolio and a large network of research and development centers. This ensures that the company is well-positioned to take advantage of the growing demand for biopharmaceuticals in the global market.
The Risks of Investing in Amgen
Investing in Amgen is not without risks. Firstly, the company is heavily reliant on the global healthcare industry and any changes in the industry could have an adverse effect on the company’s performance.
In addition, the company operates in a highly competitive market and any changes in the competitive landscape could have an adverse effect on the company’s performance.
Furthermore, the company’s stock price is subject to market volatility and any significant changes in the market could have a negative impact on the company’s stock price.
Finally, the company is heavily reliant on the success of its research and development efforts and any delays or setbacks in the development of new products or therapies could have an adverse effect on the company’s performance.
Analyzing Amgen’s Management
Amgen is well-managed and its management team has a strong track record of delivering value to its shareholders. The company has a diverse management team with experience in the healthcare industry.
In addition, the company has a strong focus on research and development and has invested heavily in its research and development efforts. This ensures that the company is well-positioned to take advantage of the growing demand for biopharmaceuticals in the global market.
The company also has a strong focus on cost-efficiency and has implemented a number of cost-saving initiatives. This helps to ensure that the company is able to remain competitive in the market and deliver value to its shareholders.
Finally, the company has a strong focus on corporate governance and is committed to maintaining a transparent and ethical business environment. This helps to ensure that the company is able to maintain its reputation in the market and protect the interests of its shareholders.
Exploring Amgen’s Business Model
Amgen’s business model is focused on developing innovative products and therapies that improve the lives of patients suffering from various diseases. The company has a diversified product portfolio and a large network of research and development centers. This ensures that the company is well-positioned to take advantage of the growing demand for biopharmaceuticals in the global market.
In addition, the company has a strong focus on cost-efficiency and has implemented a number of cost-saving initiatives. This helps to ensure that the company is able to remain competitive in the market and deliver value to its shareholders.
Furthermore, the company has a strong focus on corporate governance and is committed to maintaining a transparent and ethical business environment. This helps to ensure that the company is able to maintain its reputation in the market and protect the interests of its shareholders.
Finally, the company has a strong focus on research and development and has invested heavily in its research and development efforts. This ensures that the company is well-positioned to take advantage of the growing demand for biopharmaceuticals in the global market.
Amgen’s Future Outlook
Amgen is well-positioned for long-term success. The company has a strong presence in the global market and is well-positioned to take advantage of the growing demand for biopharmaceuticals in the global market.
In addition, the company has a strong balance sheet and a debt-to-equity ratio of 0.47. This indicates that the company is in a strong financial position and is well-positioned to take advantage of growth opportunities in the future.
Furthermore, the company has a strong track record of delivering value to its shareholders. In the last 12 months, the company’s stock price has increased by more than 27%. This is a reflection of the company’s strong performance and its ability to capitalize on opportunities in the market.
Finally, the company has a diversified product portfolio and a large network of research and development centers. This ensures that the company is well-positioned to take advantage of the growing demand for biopharmaceuticals in the global market.
Conclusion
In conclusion, investing in Amgen is a great opportunity for investors. The company has a strong presence in the global market and is well-positioned to take advantage of the growing demand for biopharmaceuticals in the global market. The company has a strong balance sheet and a debt-to-equity ratio of 0.47. This indicates that the company is in a strong financial position and is well-positioned to take advantage of growth opportunities in the future. Furthermore, the company has a strong track record of delivering value to its shareholders. In the last 12 months, the company’s stock price has increased by more than 27%. This is a reflection of the company’s strong performance and its ability to capitalize on opportunities in the market.
Therefore, investing in Amgen can be a great opportunity for investors who are looking to benefit from the company’s long-term growth prospects. With a diversified product portfolio and a large network of research and development centers, the company is well-positioned to take advantage of the growing demand for biopharmaceuticals in the global market.
By investing in Amgen, investors can benefit from the company’s strong performance and its ability to capitalize on opportunities in the market. Additionally, the company is a Dow listed company, which means that it is considered to be one of the most successful companies in the world. This gives investors the assurance that they are investing in a company that is well-positioned for long-term success.